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1. Introduction
   One of the most astonishing and important applications in the 
field of immunology in the last century was the invention and 
development of the vaccines. It was a significant leap forward 
in the prevention of infectious diseases that saved the lives of 
millions of people. The principal study started in this field was 
the experiment conducted by Edward Jenner in 1798, when he 
demonstrated that inoculation with pus from cowpox lesions was 
conferring protection and assurance against smallpox infection. 
This was a milestone ever in the history of immunology[1]. 
Subsequently, this prompts to the extermination of the smallpox 
through an innovative contribution to immunization[2]. 
   As a matter of fact these experiments establish the premise 
of vaccinology, the principle of isolation, inactivation, and 
administration of disease causing pathogens and hence treatment 
of infectious diseases. Later, there has been nonstop advance in 
producing safe and highly efficient vaccines against a number 
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of common diseases. These vaccines contained bacterial toxoids 
(diphtheria and tetanus); killed entire organisms (e.g. typhoid, 
cholera, pertussis and the Salk polio vaccine); or live attenuated 
organisms (reduce its pathogenicity) (e.g. Bacillus Calmette 
Guerin, yellow fever, the Sabin polio vaccine, measles, mumps and 
rubella)[3].
   Currently, with the advance in the biotechnology and the 
utilization of novel techniques in molecular biology, it is 
conceivable to make new vaccines. For instance, the utilization of 
yeast cell to express hepatitis B antigens was the first and strikingly 
fruitful recombinant protein vaccine. This vaccine has been highly 
effective in preventing hepatitis B viral infection and thusly 
became the first vaccine, which has the capability to prevent a 
human cancer, the hepatocellular carcinoma, associated with early-
acquired, persistent hepatitis B infection[4].
   The successful vaccine gives a fruitful opportunity to use it not 
just as a part of the term prophylaxis of infectious diseases but also 
to broaden their purposes in controlling existing and persisting 
infectious diseases. For instance, vaccines are being investigated as 
an approach to control HIV and other incessant viral infections as 
well as treatment of cancer and autoimmune ailments[5-7].
   In spite of all these accomplishment underway in production 
of vaccines, there are major challenges facing with difficulties, 
constraints and drawbacks confronting vaccination.
   Researchers were unable to produce a vaccine for pathogens with 
antigenic hypervariability including serogroup B meningococcus, 
HIV and HCV) or against pathogens with an intracellular phase, 
causing infections that are transcendently controlled by T cells, 
such as tuberculosis and malaria[8]. Likewise, development of 
conventional vaccination can be time and labor intensive, not 
permitting a quick action to the need of a new vaccine, as in the 
occurrence of an influenza pandemics. Also there are likewise 
hypothetical safety concerns linked with the approaches of using 
both non-live and attenuated concepts[9,10]. To overcome all these 
challenges, new approaches amid the most recent 30 years have 
been applied to vaccine advancement. These updated approaches in 
vaccination technology included recombinant DNA, polysaccharide 
chemistry and more recently reverse vaccinology, structural 
vaccinology, and synthetic RNA vaccines are all opening up the 
perspective for the outlining and advancement of „third generation‰ 
vaccines, beforehand characterized as impossible to make[11].
2. Conventional vaccine 
   Conventional vaccines or traditional vaccines based on inactivated 
or live attenuated microorganisms or on purged pathogen subunits, 
such as toxins, polysaccharides and proteins, have been extremely 
productive in averting infections of pathogens. The mechanism 
by which these vaccines works are fundamentally by inspiring 
functional antibodies that can neutralize viral invasion, neutralize 
bacterial toxins and induce opsono-phagocytosis or complement-
dependent bacteriolysis[12,13]. 
   Today most of the licensed vaccines are conventional vaccine. 
The current use of these vaccines leads to extraordinary 
accomplishments, such as the annihilation and the virtual 
disappearance of smallpox and diseases like diphtheria, tetanus, 
poliomyelitis, pertussis, measles, mumps, rubella and intrusive 
Haemophilus influenzae type B, increasing the life quality and 
expectancy[12,13]. However, using conventional vaccines was 
time consuming and taken a years or decades of research. Also, 
some microorganisms are difficult to cultivate or even to attenuate 
that brings about adverse or undesirable immune responses 
demonstrating that these approaches are unfeasible in some 
instances[14]. Moreover, the vast majority of the techniques used so 
far to acquire and purge the target antigen were failed which result 
in less suitable vaccine candidates[15].
3. Polysaccharide chemistry and glyco-conjugate vaccines
   In the course of the most recent decades, capsular polysaccharides 
have been successfully used in the preparation of antibacterial 
vaccines. The commercialisation of several polysaccharide-protein 
conjugate vaccines was a breakthrough aimed at filling the gaps in 
many areas, which can prevent most childhood deaths. Immunisation 
by vaccines made out of plain bacterial polysaccharides has been 
acquainted subsequent to the 1970s to control diseases caused 
by clinically important bacteria such as Haemophilus influenzae 
type B, Streptococcus pneumoniae (S. pneumoniae) and Neisseria 
meningitidis (N. meningitidis) group[16-18]. 
   Carbohydrates are substantial molecular destination in the 
evolution of vaccines against cancer, viral and bacterial infections, 
and many other diseases. However, one of the major immunological 
problems faced in the development of polysaccharide vaccines 
has been referred or due to that carbohydrates are usually poorly 
immunogenic and cannot induce a T cell-dependent immune 
response that is necessary for protective immunity and therefore, it 
is less effective especially in children (aged below two years) and 
infants who represent the main target population of vaccination[19,20]. 
   To solve this dilemma of poor immunogenicity, the carbohydrate 
molecules have to be coupled to a carrier protein, to enhance their 
immunogenicity. By facilitating access to structures of increasing 
complexity many carbohydrate-protein coupling techniques have 
been applied to develop several polysaccharide-protein conjugate 
vaccines, which filled the gap in many areas, especially for children 
and infant vaccination. The current progress in glycol-chemistry has 
facilitated the design of adequate and highly sophisticated glyco-
conjugate vaccines using synthetic saccharide components, which 
are imitative epitopes that naturally involved such protection[21]. 
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   One of these approaches is an establishment of vaccine based on 
the linkage of an orthogonal azido-protein (the univalent group N3- 
derived from hydrazoic acid) group to the carbohydrate molecule 
during and after their syntheses; such univalent group can be 
selectively reduced to a free amino group, to which a N-pentenoyl 
protecting group can be distinctly and region expressly linked. Since 
the azido group is orthogonal to most conversions that implicated in 
carbohydrate synthesis, it can be introduced at an early stage of the 
synthesis. Furthermore, the link between the 4-pentenoyl group and 
the carbohydrate molecule after synthesis would somewhat facilitate 
the synthetic design of complex carbohydrates, including the 
design of protecting strategy[22]. Subsequently, immunisation with 
proteinăpolysaccharide conjugate vaccines has the capacity to incite 
a long last immune response, with high affinity IgG antibodies and 
with the ability to be boosted by subsequent immunizations[18,23,24]. 
Proteinăpolysaccharide conjugate vaccines were introduced in the 
1980s against Haemophilus inﬂuenzae type B, inducing a better and 
persistent antibody response in all age groups[25-27]. Today, different 
approaches to prepare conjugate vaccines can be followed and 
adequate glyco-conjugate vaccines are available for S. pneumoniae 
and the different strains of N. meningitidis[28,29]. 
   On the other hand, although the advancement made in the 
innovation of glyco-conjugate vaccines made the successful control 
of distinctive bacterial infections conceivable, this approach could 
not be utilised to develop N. meningitidis type B (MenB) vaccine[30]. 
Regardless of the availability of effective antibiotics MenB, is 
a major cause of meningitis and sepsis subversive diseases that 
can kill children and young adults within hours[31]. It is a Gram-
negative bacterium part of the commensal flora that colonizes the 
upper respiratory tract of healthy individuals. In a small proportion 
of cases, the bacterium can invade the host bloodstream and, after 
crossing the bloodăbrain barrier, cause meningitis[32,33]. The 
unsuccessful endeavor of developing a MenB vaccine in view of its 
capsular polysaccharide was to a great extent because of the fact that 
it is identical to the polysialic acid present in human glycoproteins, 
for example, neural cell adhesion molecule. Numerous endeavors 
coordinated to the development of a protein-based vaccine were all 
disappointed by the inconsistency of the data probably due to the 
utmost variability of the well-known surface proteins examined as 
vaccine antigens. 
   Generally speaking new strategies and approaches may open new 
perspectives in vaccine research devoted to prophylactic and/or 
therapeutic applications against bacterial, fungal, parasitic or viral 
infections, and certain cancers. 
4. Reverse vaccinology  
   A critical upheaval in vaccine disclosure is connected to the 
approach of genome sequencing innovations that have changed the 
scene in the gradually advancing field of immunology. The defining 
moment was the publication documented in 1995 of the genome 
arrangement of the first living organism[34]. By sequencing the 
genome and by characterizing the entire antigenic repository of 
the infectious microorganism, several contender protective targets 
could be distinguished and tested for their suitability as vaccine. The 
technique, named reverse vaccinology, has implemented a change 
in the viewpoint of vaccine design. The thought of the reverse 
vaccinology was started to conquer the issues confronted to develop 
vaccine with high adequacy against MenB. The genome sequencing 
of the MenB pernicious strain MC58 permitted a selection to choice 
for the potential vaccine targets from the genomic data bank[35,36]. 
The precept at the foundation of the reverse vaccinology path was 
that, felicitous vaccine targets were proteins either expressed on 
the surface of the microorganism or excreted into the extracellular 
environs. About 600 surface-exposed proteins were predicted and 
successfully expressed using bioinformatics analysis. Of these, about 
350 were cloned in Escherichia coli (E. coli), expressed and used to 
immunize animal model. The sera of such animals were examined 
using a bactericidal assay that is well known to correlate with 
protection. This screening procedure allowing a selection criteria 
which are necessary in order to select the most feasible candidates 
to be discarded are not satisfying quality benchmark. Therefore, 
the process elicited the identification of previously obscure vaccine 
candidates. Through this process three protective antigens that 
are common to multiple MenB strains have been filtered and 
characterised and named as factor H-binding protein, Neisseria 
adhesin A, and neisserial heparin-binding antigen and combined 
with a MenB outer membrane vesicle, resulting in the first universal 
vaccine against MenB[37,38]. 
   This was the first vaccine developed using reverse vaccinology 
technology that holds a positive feedback from the European 
Medicines Agency and has been ratified with the commercial name 
of Bexsero®. Following the success of this project, the reverse 
vaccinology technology has been utilized in a wide range of other 
clinically important pathogens, such as S. pneumoniae[39,40], 
Streptococcus pyogenes[41], Chlamydia pneumonia[42], Chlamydia 
trachomatis[43], Streptococcus agalactiae[44], E. coli[45], and 
Leishmania major[46]. Consequently, the genome-based reverse 
vaccinology approach can rig out adequate and innovative strategies 
to design vaccines that were found to be difficult or even unattainable 
to develop using conventional approaches[46]. 
5. DNA immunization
   Genetic immunization or DNA vaccination, a rapidly developing 
technology which has been described as a third generation of 
vaccines[47], offers new approaches for the prevention and therapy 
of several diseases of both bacterial and viral origin[48,49]. DNA 
Sidgi Syed Anwer Abdo Hasson et al./Asian Pac J Trop Biomed 2015; 5(5): 344-353 
immunisation has also emerged in the last decade as a strikingly 
novel approach to immunoprophylaxis[50], and has been widely used 
in laboratory animals and non-human primates over the last decade 
to induce antibody and cellular immune responses[51]. 
   Successful in vivo transfection of mammalian cells following 
injection of purified DNA was first reported over 40 years ago[52]. 
However, its potential went largely unrealised until 1990 when 
Wolff and colleagues demonstrated that a reporter gene encoding 
an enzyme protein could be expressed in murine skeletal muscle in 
vivo and the tissue retained its transgenic biological activity for up to 
60 days after inoculation[53]. These observations were extended by 
several studies such as those of Tang et al., (1992) who demonstrated 
that mice injected with plasmid DNA encoding human growth 
hormone elicited antigen-specific antibody responses[54]. Based on 
these findings, it is concluded that this technology is promising as it 
can enhance both cellular and humoral immunity against parasites, 
bacteria and disease-producing viruses[55-57].
5.1. Advantages of DNA vaccines  
   The ability of plasmid DNA to induce both cellular and humoral 
immune responses after inoculation has been demonstrated in several 
animal models, and hopes have been raised that its applications will 
lead to new therapies for a range of human diseases[58,59]. Since the 
first published report on the protective immune responses against 
infectious diseases in animals, several studies were performed to 
evaluate the safety and immunogenecity of DNA vaccination in 
humans, and many studies are still ongoing up to date. 
   It is potentially cheaper to produce than recombinant protein 
vaccines. It is much easier to transport and use, especially in 
developing countries, DNA-based immunisation exhibits several 
important advantages over conventional immunisation strategies 
that involved live-attenuated or killed pathogens, proteins, or 
synthetic peptides. It incorporate many of the most attractive features 
of each approach. One of the important advantages of the DNA 
immunisation[60], is that the immune response to immunisation can 
be directed to elicit either humoral or cellular immune responses 
or both without the need for live vectors or complex biochemical 
production techniques. Other advantages of DNA vaccines are that 
they are highly specific and the expressed immunizing antigen 
is subjected to the same glycosylation and post-translational 
modifications as natural viral infection. Moreover, it is relatively 
easier to insert multiple variants of an antigen into a single array 
of plasmid vaccine[61-63]. Candidate bacterial antigens can now 
be chosen from genomic sequences and plasmid vaccines permit 
much simpler taking advantage of this new data than the alternative 
of developing a good expression system for each antigen and then 
setting up the recombinant protein. This is a considerable advantage 
for curative vaccination against tumor antigens which may be 
identified only as DNA sequences produced from both human and 
cancer genomes[61-63].
   Logistic advantages of DNA vaccines include the relative ease 
and low cost of production and transportation making them more 
suited to production in the developing world than other systems. 
A summary of these perceived advantages of DNA vaccines is 
illustrated in Figure 1[64]. 
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Figure 1. Summary of relative advantages of DNA vaccines over 
conventional vaccines[64].
MHC: Major histocompatibility complex. 
5.2. Disadvantages of DNA vaccines
   The disadvantages of DNA vaccines are based mainly on health 
and safety issues. Most of the safety issues concerning the system 
are based on the activation of oncogenes as a result of genomic 
incorporation of immunising DNA[65], as well as eliciting anti-DNA 
antibodies; however, this has rarely been detected in experimental 
studies[60]. While these issues are of concern and require careful 
monitoring, it would not be applied to DNA immunisation of captive 
animals to produce antibodies, particularly if gene gun is used. This 
is due to the likelihood of eliciting anti-DNA antibodies when use 
of the gene gun is minimised because it requires 100-fold less DNA 
than intramuscular injection to achieve equivalent seroconversion 
efficiencies[66]. Other drawback of plasmid vaccines is the reduced 
level of immunogenicity[67]. Therefore, adequate adjuvants will 
be necessary to overcome this impediment. One of the suggested 
solutions is to integrate the plasmid, genes for those cytokines such 
as interleukin 4 or granulocyte-macrophage colony-stimulating 
factor that enhances immune responses or for C3d oligomers as an 
adjuvant for B-lymphocyte cells. Other likely approach may include 
an ensuing booster immunisation with the relating antigen as a 
protein.
 
5.3. Principles of DNA immunisation
   DNA vaccination involves the introduction of nucleic acid into host 
Sidgi Syed Anwer Abdo Hasson et al./Asian Pac J Trop Biomed 2015; 5(5): 344-353
cells where it directs the synthesis of its encoded polypeptide(s) and 
stimulates an immune response[68]. Unlike gene therapy, genetic 
integration is not intended. Indeed, the construction of a DNA 
vaccine is designed to permit localized, short-term expression of the 
target antigen. 
   Although several attempts have been made to study the cellular 
pathways for the processing of antigens and their presentation to T 
lymphocytes, the precise mechanism based on cellular and molecular 
events involved in the induction of immune responses following 
DNA immunisation are not fully understood[69]. However, it is 
well documented that the magnitude and type of immune response 
induced after DNA immunisation are influenced by a number of 
different parameters, some of which are represented by the type and 
components of the expression plasmid. 
5.4. Essential components of a DNA plasmid
   A typical „first generation‰ DNA vaccine plasmid requires (i) 
the incorporation of a strong viral promoter to achieve optimal 
expression in mammalian cells[70], such as cytomegalovirus or 
simian virus 40 which provide the greatest gene expression; (ii) an 
origin of replication allowing plasmid propagation in E. coli; (iii) 
a bacterial antibiotic resistance gene (this allows plasmid selection 
during bacterial culture); and (iv) a transcription-stop sequence such 
as bovine growth hormone 3Ê-untranslated region (Figure 2)[70]. 
Figure 2. A schematic representation of a simple DNA plasmid[70]. 
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5.5. The influence of mode and site of gene delivery
   Several studies have shown that the type of immune responses 
induced by plasmid immunisation is significantly affected by (i) 
the mode and site of gene delivery, (ii) the dose of plasmid and (iii) 
the administration of booster injections and the interval between 
immunisations[71]. 
   In general, immunisation with DNA can be accomplished in two 
fundamentally different ways. One approach is the use of needle 
injection into different tissues, the most effective route being 
intramuscular injection into the hind leg quadriceps or tibialis 
anterior[72,73], followed by intradermal injection[74-76]. These routes 
usually provoke strong, antigen-specific Th1-biased, humoral and 
cellular immune responses[76,77]. 
   An improvement in efficacy of plasmid transfection was achieved 
by injection of DNA into regenerating skeletal muscle, achieved 
by prior injection of either cardiotoxin or local anaesthetic 
such as bupicaine[51]. Several methods have been investigated 
to improve delivery of DNA vaccines including (i) mechanical 
delivery consisting of microinjection by various types of needles 
including pressure injection, (ii) electrical delivery (electroporation, 
ionophoresis) and (iii) chemical (liposomes and various polymers)
[78-82] and mucosal delivery (Figure 3). Each one of these methods 
of delivery introduces plasmid DNA into distinct areas of immune 
surveillance and therefore primes the immune system in distinct 
ways. 
Figure 3. Schematic illustration of electroporation mediated transfection. 
a: Intramuscular injection; b: Electroporation; c: Transient increased 
permeability of cell membrane (yellow arrows) results in plasmid transfer 
into the cell; d: Resting of cell membrane (red arrow).
(a)
(c) (d)
(b)
   Gene gun delivery of DNA which propels the DNA-coated gold 
particles into the epidermis[83,84] resulted in a more Th2 biased 
antibody isotype response and efficient humoral and cellular 
responses[76,77]. The distinct Th1- or Th2-biased immune responses 
elicited by intramuscular injection or gene gun delivery, respectively, 
are not fully understood. Bacterial DNA contains CpG motifs that 
induce non-specific Th1-dominant responses. Gene gun delivery 
requires 100-1000 fold less DNA to stimulate immune responses 
to that achieved by intramuscular injection. The reduced number 
of Th1-promoting CpG motifs involved in gene gun immunisation 
may therefore explain the Th2-bias response to gene gun DNA 
vaccination. 
5.6. Antigen presentation following DNA immunisation
   An important step in the design of DNA immunisation constructs is 
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to understand the immune correlates of protection. Antigen peptides 
expressed after DNA immunisation are usually presented by antigen-
presenting cells (APCs) in the context of either MHC class II or 
class I molecules to CD4+ and CD8+ T cells, respectively. There 
are at least three means by which MHC class Iărestricted cytotoxic 
T-lymphocyte (CTL) might be elicited following administration 
of plasmid DNA: (i) transfection of professional APCs, (ii) antigen 
presentation mediated directly by transfected myocytes or, (iii) cross 
priming[64], as illustrated in Figure 4[69].
Figure 4. Mechanisms of antigen presentation following DNA 
immunisation[69]. 
a: Antigen presentation mediated directly by transfected myocytes; b: 
Transfection of professional APCs; c: Cross priming.
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5.6.1. Transfection of professional APCs 
   The immune response following DNA immunisation was found to 
be dependent upon professional APCs, specifically bone marrow-
derived dendritic cells (DC)[85]. In 1997, Fu and colleagues[86] 
demonstrated that when parental bone marrow chimeras were 
immunised with plasmid DNA encoding influenza nucleoprotein 
by intramuscular injection and gene gun, CTL responses were 
specific to the peptide presented by the MHC class I molecules 
found on the donor bone marrow[87] (Figure 4b)[69]. Furthermore, 
the same authors reported that, although only a small proportion of 
the DCs were transfected with plasmid DNA, it was noticeable that 
there was general activation (maturation) and migration of large 
number of DCs that had not been transfected. However, whether 
this generalised maturation of untransfected DCs could also present 
antigen via additional mechanisms remains uncertain.
5.6.2. Antigen presentation mediated directly by transfected 
myocytes 
   Ulmer et al. (1993)[88], by demonstrating that direct intramuscular 
inoculation of plasmid DNA induced a strong CD8+ CTL to 
influenza nucleoprotein, provided the first evidence that cellular 
responses could be induced in vivo by DNA immunisation and the 
induced immune responses had a potentially important protective 
role. Subsequent experiments were then undertaken to directly test 
whether DNA-transcribed muscle cells alone are sufficient to prime 
immune response (Figuer 4a)[69]. However, Iwasaki et al. (1997)
[89], reported that muscle cells failed to prime CTLs responses 
when injected with DNA plasmid encoding CD86 or granulocyte-
macrophage colony-stimulating factor only (i.e., without antigen). 
To examine the contribution of both bone marrow- and non-bone 
marrow-derived cells to CTL priming, Agadjanyan et al. (1999)[90] 
found that antigen-specific CTL responses could be induced by 
non-bone marrow-derived (muscle) cells only when mice were 
immunised with DNA encoding either the antigen or CD86. Surgical 
ablation experiments have been used to identify the contribution 
of antigen expression in tissues subjected to DNA immunisation 
by distinct routes. Torres et al. (1997) demonstrated that removing 
the DNA-injected muscle bundle within 10 min of DNA injection 
had no effect on the longevity and magnitude of humoral and CTL 
responses[91], suggesting a rapid migration of transfected cells or 
plasmid DNA from the site of injection. These authors also found 
that excision of the epidermal site 24 h after gene gun bombardment 
abrogated the induction of CTL responses, suggesting that the 
immune response was dependent on the transfected epidermal cells. 
This finding indicates that intramuscular injected plasmid DNA is 
likely to gain rapid access to the lymphatic or circulatory system, 
thus obviating the need for transfection of muscle cells at the site 
of injection. In conclusion, these data indicate that DCs such as 
Langerhans and myocytes play a crucial role in the primary response 
triggered by DNA vaccines. 
5.6.3. Cross priming
   Cross priming has been suggested as a mechanism to explain 
antigenic transfer from DNA-transfected somatic cells to professional 
APCs (Figure 4c)[69]. The concept of cross priming, in which 
triggering of CD8+ T-cells responses can occur without de novo 
antigen synthesis within the APCs, was first described by Ulmer 
(1996)[92] and Fu (1997)[86] and provides an additional mechanism 
by which DNA immunisation can enhance immune responses. 
During cross priming, antigens or peptides expressed by DNA-
transfected myocytes or DCs presented in context of either MHC I or 
II can be taken up by professional APCs to prime T-cell responses. 
Thus, DNA-transfected myocytes or DCs may serve as antigen-
producing „factories‰ which magnify and maintain the immune 
response via cross priming[93,94]. 
6. Strategy of DNA immunisation in the development of 
clinical trial 
   The remarkable advance and diverse applications of DNA 
immunisation attracted the attention of many researchers as an 
alternative procedure for analysing the structure and expression of 
genes in general[95], studies for improving the treatment of several 
diseases[96-99], and clinical trials soon ensued. 
   Owing to the promise of DNA vaccines in studies using small 
animal model, clinical trials were soon ensued. The primary of a 
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few of phase I trials, performed almost 2 decades back, assessed 
the adequacy of a DNA vaccine targeting HIV-1 for therapeutic and 
prophylactic usage[100]. Subsequent studies conducted after that 
focused on other diseases such as cancer, human papillomavirus, 
hepatitis, malaria, influenza, and other HIV-1 antigens. 
   Nonetheless, the results of these early clinical trials were thwarting. 
The DNA vaccines were intact and well abide, yet they turned 
out to be inadequately immunogenic. The antibody titers induced 
has been found to be very low or absent; CD81 T-cell responses 
were desultory, and CD41 T-cell responses were of low frequency. 
However, these studies provide substantiation of connotation that 
DNA vaccines could safely induce immune responses[100]. Numerous 
improvements have been integrated into the present DNA vaccines, 
and these improvements have assist to gleam a revival of interest 
in the dais. Although the subsequent or the second generation DNA 
vaccines seem to influence towards both humoral and cellular 
immune responses regardless of animal models used, researchers 
suggested that new modified DNA vaccines can be more efficient 
by broadly activate CD8+ CTLs in larger animal models, compared 
with previous approved DNA methods[101]. The reduced level of 
immunogenicity of precocious DNA vaccines is speculated to stem, 
due to the inefficiency of cellular uptake of the inoculated plasmids. 
   Current research is focusing on developing neoteric approaches 
to promote transfection competence and improve other facets of the 
DNA platform. Such neoteric approaches involve optimization of 
the antigens encoded by the plasmids to increase antigen expression 
on a per-cell basis, enhance formulation, and inclusion of molecular 
adjuvants to promote and direct immune responses[99]. Up to date 
there are about 43 clinical trials evaluating DNA vaccines for viral 
and non-viral ailments recorded in the gene database clinical trials. 
The majority of the recorded trials are investigating vaccines for HIV 
and cancers. The remaining are investigating vaccines for human 
papillomavirus, malaria, influenza, and hepatitis B and C viruses[99]. 
Furthermore, in the available trials there is currently a lack of long-
term follow up. Ideally, the availability of data from randomized 
clinical trials featuring robust end points such as biochemical 
response, progression free and overall survival will provide 
categorical evidence for DNA vaccinationÊs potential.
7. Conclusions
   Development of the vaccines is one of the most astonishing 
and important applications in the field of immunology in the last 
century. It was a major achievement in the prevention of infectious 
diseases that saved the lives of millions of people. currently most of 
the licensed vaccines are conventional. DNA vaccine is potentially 
cheaper to produce than recombinant protein vaccines. It is much 
easier to transport and use, especially in developing countries. 
Importantly, DNA-based immunisation exhibits several advantages 
over conventional immunisation strategies that involved live-
attenuated or killed pathogens, proteins, or synthetic peptides. It 
incorporate many of the most attractive features of each approach. 
One of the important advantages of the DNA immunisation is that 
the immune response to immunisation can be directed to elicit either 
humoral or cellular immune responses or both without the need for 
live vectors or complex biochemical production techniques. The 
disadvantages of DNA vaccines are based mainly on the activation 
of oncogenes as well as elicitation of anti-DNA antibodies and low 
immunogenicity in vaccines. However, these issues are of concern 
and required to be resolved based on both scientific and clinical 
research studies.  
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Comments 
Background
   The review is mainly focused on the scientific and clinical 
approach in both the conventional and the new approach of DNA 
vaccines. During the last two decades, there has been formidable 
progress in the field of DNA immunization. This has been an 
outcome of new and better vectors, distinctive types of delivery 
strategies, which is activated by either the expression of DNA 
plasmid itself and/or by encoded proteins. The present review brings 
together primary data and up-to-date summaries and outlines the 
great leaps forward in utilizing DNA plasmids for immunizations and 
immune-therapies.
  
Research frontiers
   The present review depicts and illustrates the past and current 
trends of DNA vaccine, denoting the last two decades since the 
early substantiation of preclinical protection of vaccine. In general 
the present review brings together primary data and up-to-date 
summaries and outlines leaps forward in utilizing DNA plasmids for 
immunizations and immune-therapies. In addition the review gives 
sufficient information for the clinicians as well as the researchers to 
exploit the therapeutic drugs for the prophylaxis against the untreated 
diseases.
Related reports
   A large number of articles are available on immunization and DNA 
vaccination. However, the present work is different from previously 
published reports and reviews in the fact that it gives detailed 
information of the scientific and clinical applications as well as the 
updated technology of both conventional and DNA immunization. 
Also it reflects the basis of recent and excellent research works in 
such field with an excellent flow of data since an early stages of 
immunization.
Innovations and breakthroughs
   The authors have tried to present the history, current work and 
the future trends of immunisation with the new technology of 
DNA vaccine. The authors also illustrated the main advantages and 
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disadvantages of the old and new era of immunization and DNA 
vaccine in general, showing that the current conventional treatments 
are not satisfactory and are full of adverse effects. Moreover, the 
authors have taken note of the old and current reports with adequate 
references to build strong statements and polymerize our knowledge 
on the concept of DNA immunization by providing an excellent 
prediction of the future of DNA vaccination to understand. It is really 
interesting to see a review that summarizes and brings together 
all what has been said from an early stage of immunisation to the 
prediction of our future concept on DNA technology and vaccination.

Applications
   From the literature survey, the authors tried to demonstrate the 
applications with their drawbacks based on DNA vaccination, and 
showed the future prospects that whether or not it is safe or need an 
attention to rectify any major or minor issues related to human health 
and safety.
Peer review
   This is a valuable and systematic review in which the authors 
have clearly focused on the scientific and the clinical applications of 
DNA immunizations. The manuscript was witten in a way that was 
informative and unbiased with the general and current principles and 
concept of DNA vaccines technology and provided a summary of the 
novel approaches to the DNA vaccine, in parallel with its descriptive 
mechanism(s) of protective immunity induced.
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